Share information
221.80 €
-1.95 %
12/08/2026 17:35
-1.95 %
Open
High
Low
Volume
224.90 €
225.70 €
219.20 €
178,654
Latest News
30-Jul-2026
UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase
08-Jul-2026
UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026
17-Jun-2026
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
17-Jun-2026
UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline